Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
21 Fevereiro 2024 - 9:00AM
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome
editing company, today announced that it will host a conference
call and webcast on Wednesday, February 28, 2024, at 8:00 a.m. ET
to discuss results for the fourth quarter and full year 2023 and to
provide a corporate update.
To access the conference call:
- U.S. callers should dial +1-877-407-0989 and international
callers should dial +1-201-389-0921 approximately five minutes
before the call begins.
- Participants should ask to be connected to the Editas Medicine
Earnings Conference Call.
The conference call will also be webcast and can be
accessed from the “Investors” section of the Editas Medicine
website at https://www.editasmedicine.com. A replay will be
available at the same site approximately one hour after the
completion of the call.
In addition to the conference call, management will
participate in the following upcoming investor conferences:
- TD Cowen 44th Annual
Health Care ConferenceFormat: Fireside ChatDate: Monday,
March 4Time: 12:50 p.m. ETLocation: Boston, MA
- Leerink Partners Global Biopharma
ConferenceFormat: Fireside ChatDate: Tuesday, March
12Time: 10:40 a.m. ETLocation: Miami Beach, FL
- Barclays 26th Annual
Global Healthcare ConferenceFormat: Fireside ChatDate:
Wednesday, March 13Time: 2:05 p.m. ETLocation: Miami Beach, FL
To access the live webcasts of Editas Medicine’s
presentations, please visit the “Investors” section of the
Company’s website at www.editasmedicine.com. An archived replay
will be available for approximately 30 days following each
event.
About Editas
MedicineAs a clinical-stage genome editing company, Editas
Medicine is focused on translating the power and potential of the
CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust
pipeline of treatments for people living with serious diseases
around the world. Editas Medicine aims to discover, develop,
manufacture, and commercialize transformative, durable, precision
genomic medicines for a broad class of diseases. Editas Medicine is
the exclusive licensee of Broad Institute’s Cas12a patent estate
and Broad Institute and Harvard University’s Cas9 patent estates
for human medicines. For the latest information and scientific
presentations, please visit www.editasmedicine.com.
Media and Investor Contact:
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com
Editas Medicine (NASDAQ:EDIT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Editas Medicine (NASDAQ:EDIT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024